小干扰RNA用于治疗脱脂症的更新
S Carugo1,2, C R Sirtori3, G Gelpi2
1Department of Clinical Sciences and Community Health, Dyspnea Lab, Università degli Studi di Milano, Milan, Italy.
Current atherosclerosis reports
|October 4, 2023
概括
基于RNA的疗法为管理复杂的脂质障碍提供了新的希望,例如失脂症. 这些创新的治疗方法针对难以管理的疾病,改善心血管健康并降低动脉样硬化心血管疾病的风险.
科学领域:
- 心血管医学 心血管医学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 动脉样性心血管疾病 (ASCVD) 仍然是全球主要的死亡原因.
- 许多患有脱脂症的患者没有得到足够的治疗,这凸显了对先进疗法的需求.
- 除了LDL-C,脂蛋白和富含甘油三蛋白的脂蛋白对心血管风险至关重要.
研究的目的:
- 审查基于RNA的疗法在治疗脱脂症治疗中的新兴作用.
- 讨论新药在降低动脉样硬化心血管疾病 (ASCVD) 风险方面的潜力.
- 探索RNA疗法在挑战性脂质疾病中的应用.
主要方法:
- 对基于RNA的降脂剂最近的临床试验数据的审查.
- 对针对LDL-C,脂蛋白和甘油三的siRNA疗法的安全性和疗效发现的分析.
- 对药理动力学概况和剂量策略的评估.
主要成果:
- 英克利西兰在降低LDL-C方面显示出长期的安全性和有效性,并有可能减少心血管事件.
- 奥尔帕西兰显示脂蛋白水平的剂量依赖性降低,适合12周的管理.
- 像ARO-APOC3和ARO-ANG3这样的新兴疗法有效地降低了apoC-III和ANGPTL3,尽管仍处于早期发展阶段.
结论:
- 基于RNA的疗法,特别是siRNA,代表了治疗脱脂症的有前途的新型药物.
- 这些药物提供了有针对性的方法来管理复杂的脂质配置文件并降低ASCVD风险.
- 开发RNA疗法对于心血管疾病的个性化风险管理至关重要.
更多相关视频
09:09Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
Published on: May 2, 2019
7.5K
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
10.7K
相关概念视频
Small interfering RNAs (siRNA)
3.6K
3.6K
siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
Experimental RNAi
6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
RNA Interference
26.1K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.1K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
681
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
681
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
